Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China.

CONCLUSIONS: Olmesartan/amlodipine fixed-dose combination confers better health outcomes and costs less compared with olmesartan and amlodipine free combination and valsartan/amlodipine fixed-dose combination and is cost-effective compared with amlodipine for hypertension treatment in China. PMID: 31782677 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research